Helius Medical Technologies, Inc. (NASDAQ:HSDT) Sees Large Decrease in Short Interest

Helius Medical Technologies, Inc. (NASDAQ:HSDT) was the recipient of a significant decline in short interest in August. As of August 15th, there was short interest totaling 31,400 shares, a decline of 23.4% from the July 31st total of 41,000 shares. Based on an average trading volume of 452,900 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 452,900 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised Helius Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, Helius Medical Technologies presently has a consensus rating of “Hold”.

Helius Medical Technologies Stock Performance

NASDAQ HSDT opened at $6.16 on Wednesday. The firm’s fifty day moving average price is $7.14 and its two-hundred day moving average price is $140.48. The stock has a market cap of $6.63 million, a PE ratio of 0.00 and a beta of 0.74. Helius Medical Technologies has a fifty-two week low of $5.37 and a fifty-two week high of $1,200.00.

Helius Medical Technologies (NASDAQ:HSDT) last posted its earnings results on Thursday, August 14th. The company reported ($79.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($128.50) by $48.77. Helius Medical Technologies had a negative net margin of 7,215.25% and a negative return on equity of 699.93%. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.11 million.

Institutional Investors Weigh In On Helius Medical Technologies

An institutional investor recently bought a new position in Helius Medical Technologies stock. Armistice Capital LLC bought a new position in shares of Helius Medical Technologies, Inc. (NASDAQ:HSDT) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 72,000 shares of the company’s stock, valued at approximately $29,000. Armistice Capital LLC owned about 17.60% of Helius Medical Technologies at the end of the most recent reporting period. 18.63% of the stock is owned by institutional investors and hedge funds.

Helius Medical Technologies Company Profile

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.